Close Menu

NEW YORK (GenomeWeb) – A team led by researchers at the Salk Institute has developed a CRISPR-Cas9 genome editing system that epigenetically activates target genes without causing DNA double-strand breaks (DSBs). As they reported today in Cell, the investigators used the new system to treat diabetes, acute kidney disease, and muscular dystrophy in mouse models.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Los Angeles brought and settled a civil enforcement action against the makers of an at-home test for SARS-CoV-2, NPR reports. 

The Guardian reports that Cancer Research UK is cutting its research funding by £44 million.

Technology Review examines factors affecting SARS-CoV-2 testing turnaround times.

In PNAS this week: mapping of ancient human migrations in Europe, recurrent gene fusion in breast cancer, and more.